Cryptosporidium is a small parasite that infects the intestines of humans and other animals, it leads to a disease known as cryptosporidiosis which has symptoms that includes diarrhea. This organism can vary in severity but the strongest case leads to mild cases of Cryptosporidiosis and our company provides invaluable services in developing vaccines against it using research based on diverse technologies making sure your research stands appropriate.
Introduction to Cryptosporidiosis
Crytosporidiosis is a waterborne disease which caused by Cryptosporidium, it targets the intestines of humans and animals. It is a severe water-borne infection that is rampant in developing countries where there and remedial measures are limited. The infection is more severe in cases such as HIV, old people, and in younger kids. In areas that are severely contaminated with water, the cases of infection are documented to be anywhere between 2% to 6% worldwide.
Fig.1 Cryptosporidium parvum life cycle. (Dumaine, J. E., J. Tandel, and B. Striepen., 2020)
Diagnosis Development of Cryptosporidiosis
For the last few years, advancements have been made in regard the diagnostic procedures for cryptosporidiosis over two key fronts:
Optimization of Quantitative PCR (qPCR)
Scientists are improving the existing infrastructure to lower the range of qPCR to lower levels of concentration detection—for instance in uninfected people and other forms of environmental factors. Simultaneous Multiplex PCR is able to identify several distinct pathogens in a single test this being highly efficient for multifaceted infections.
Development of Advanced LAMP Techniques
LAMP technologies have greatly enhanced in both their precision and their speed of diagnosis. Modern editions combine LAMP with colorimetric or fluorescent signals that are useful in significant field based diagnostics that require quick and mobile diagnosing devices.
Vaccine Development for Cryptosporidiosis
The focus of the research serves the purpose of locating the major surface antigens of Cryptosporidium capable of stimulating protective immunity. While subunit drugs have proven useful in some attempts on animal models, they remain inconsistent with humans.
This is one area of concern which is going through intense research today as the prospects of mRNA technology are being explored for application in cryptosporidiosis. One hopeful aspect of this approach is the opportunity to target specific Cryptosporidium antigen, developing and tailoring vaccines quickly, although the concept is at a preface stage of research.
Currently, attempts are being made to create live attenuated vaccines which aim to cause malfunctioning of the parasite without causing the disease by using the weakened version of the parasite. These vaccines have shown success in animal preclinical studies.
Our Services
We provide a plethora of resources to empower our clients in researching and developing novel therapeutics and vaccines against Cryptosporidiosis. Our seasoned professionals, including immunologists, scientists, and pharmacologists, deploy various sophisticated tools and advanced technologies to propel the success of your projects.
Animal Models of Cryptosporidiosis
Using our considerable knowledge, we create and utilize animal models which mimic the disease and response markers of Cryptosporidiosis. For doing detailed analysis of the pathophysiology and its findings, these models play a vital role in doing that, along with the testing of different kinds of therapies and their findings.
Pathogen Infection Models
Pathogen Infection Models are research tools used to study pathogen-host interactions without modifying or altering the genetic material of the host organism.
Optional Models：Cryptosporidium Infection Model; Cryptosporidium Infected Intestinal Injury Model
Humanized Models
Humanized Models are research systems that involve introducing human cells or tissues into non-human organisms without modifying the host organism's genetic material.
Optional Models：Humanized Immune System Model; Humanized Gut Model
The current direction of the research for the development of therapies for Cryptosporidiosis is focused in the identification and development of novel antiparasitic compounds which include small molecules, with emphasis on parasite-specific pathways and virulance targets. This involves the discovery, characterization, and optimization of candidate therapeutic agents and their subsequent evaluation as to efficacy and safety in order to allow promising candidates to move forward to preclinical stages.
If you are interested in our services, please don't hesitate to contact us.
References
- Dumaine, J. E., J. Tandel, and B. Striepen. "Cryptosporidium Parvum." Trends Parasitol 36.5 (2020): 485-86.
- Wang, B., A. Castellanos-Gonzalez, and A. C. White, Jr. "Novel Drug Targets for Treatment of Cryptosporidiosis." Expert Opin Ther Targets 24.9 (2020): 915-22.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
